about the author

Ryan Cross

Senior Science Correspondent

rcross@endpointsnews.com

Ryan Cross is the Senior Science Correspondent at Endpoints News. He joined the newsroom in 2023 after covering biotech for The Boston Globe. Before that he was at Chemical & Engineering News where he led coverage of COVID vaccines, gene editing, and all things RNA. His work has also appeared in MIT Technology Review, Science, STAT, and more. Ryan is a graduate of Boston University's master's program in science journalism, and he studied genetics, neuroscience, and medicinal chemistry at Purdue University. He currently lives in Cambridge, Massachusetts. Reach out privately on Signal: RyanCross.25

author articles

Ex­clu­sive: George Church start­up will study long-lived an­i­mals, hu­mans to find life-ex­tend­ing genes

2 days ago
Financing
Startups

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

3 days ago
Startups
R&D

Sid­dhartha Mukher­jee’s cell ther­a­py start­up nar­rows fo­cus as staff shrinks

Last week
R&D
Cell/Gene Tx

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Last week
R&D
FDA+

Tome Bio founders wran­gle ‘jump­ing genes’ to cre­ate new pro­gram­ma­ble gene in­ser­tion tool

Last week
R&D

Alzheon’s amy­loid-tar­get­ing pill fails an­oth­er Phase 3 study in Alzheimer’s

2 weeks ago
R&D

Q&A: David Liu talks about sci­ence un­der pres­sure, teas­es “dis­ease-ag­nos­tic” gene edit­ing

3 weeks ago
People

Se­cre­tive Chi­nese start­up be­gins first-ever clin­i­cal tri­al of cir­cu­lar RNA ther­a­py

3 weeks ago
R&D

RNA edit­ing start­up rais­es $155M to bring liv­er and lung dis­ease ther­a­py in­to clin­ic

4 weeks ago
Financing
Startups

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

4 weeks ago
R&D
In Focus

Ex­clu­sive: mR­NA start­up Turn Biotech­nolo­gies ac­quires Vesi­gen’s mi­crovesi­cle de­liv­ery tech

5 weeks ago
R&D

Stem cell com­pa­ny bit.bio cuts quar­ter of staff, drops ther­a­peu­tics fo­cus

Last month
People
Cell/Gene Tx

CRISPR com­pa­ny Ar­bor rais­es $73.9M to test ther­a­py in clin­i­cal tri­als

Last month
Financing
Startups

George Church spin­out de­vel­op­ing ge­nom­i­cal­ly re­cod­ed or­gan­isms cuts most em­ploy­ees

Last month
People
Startups

Ex­clu­sive: Dai­ichi Sankyo, John­son & John­son part­ner with RNA de­liv­ery start­up No­sis Bio

Last month
Deals
AI

Al­ny­lam eyes big­ger dis­eases in more tis­sue types at ‘in­flec­tion point’ for siR­NA

Last month
R&D

Will CRISPR mat­ter?

2 months ago
R&D
Special

Ex­clu­sive: CRISPR de­liv­ery start­up, based on UC Berke­ley and UCSF sci­ence, shuts down

2 months ago
Startups
R&D

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

2 months ago
Financing
R&D

New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug

2 months ago
R&D

Ex­clu­sive: Fer­til­i­ty start­up to be­gin Phase 3 study of stem cell ther­a­py for IVF

2 months ago
R&D
FDA+

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

3 months ago
R&D
China

Post-Hoc: The em­bryo edit­ing de­bate is back

3 months ago
China
Cell/Gene Tx

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

3 months ago
Deals
1234 Next page Last page
A service from the Financial Times